Panacea Biotec Secures UNICEF Order Worth US$8.2 Million for Polio Vaccine Supply
Panacea Biotec received a Letter of Award from UNICEF for supplying bivalent Oral Polio Vaccine (bOPV). The order is worth approximately US$8.205 million (₹78.24 Crore) and is to be executed in Calendar Year 2028. This is part of a long-term agreement with UNICEF.
The order value is substantial and contributes to the company's revenue stream, but it is for a future period and part of an existing agreement.
The company has received a significant order from UNICEF, which is a positive development for its business.
Panacea Biotec Limited has announced the receipt of a Letter of Award from UNICEF for the supply of bivalent Oral Polio Vaccine (bOPV). This award is part of a Long-Term Agreement for bOPV supply to UNICEF, which commenced on April 1, 2026, and extends to March 31, 2030.
The company has received a specific award for the supply of bOPV in 10 and 20 dose presentations, valued at approximately US$8.205 million (approximately ₹78.24 Crore) for the Calendar Year 2028.
This follows a previous communication on October 3, 2025, where Panacea Biotec had informed about receiving a Letter of Award from UNICEF for a Long-Term Agreement for bOPV supply covering Q2 CY2026 and CY2027. The current announcement pertains to the award for Calendar Year 2028.
The order is from an international entity, UNICEF, and the nature of the contract is the supply of bOPV. The order is to be executed within Calendar Year 2028. Panacea Biotec has confirmed that promoters, promoter group, or group companies do not have any interest in UNICEF, and the contract does not fall under related party transactions. The award was received on August 4, 2026.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under new orders. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.